| 0.1397 0.01 (7.46%) | 05-29 13:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.19 | 1-year : | 0.22 |
| Resists | First : | 0.16 | Second : | 0.18 |
| Pivot price | 0.14 |
|||
| Supports | First : | 0.11 | Second : | 0.09 |
| MAs | MA(5) : | 0.13 |
MA(20) : | 0.14 |
| MA(100) : | 0.47 |
MA(250) : | 1.29 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 16.6 |
D(3) : | 29.1 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 3.85 | Low : | 0.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SSKN ] has closed above bottom band by 15.1%. Bollinger Bands are 81.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.14 - 0.14 | 0.14 - 0.14 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.13 - 0.13 | 0.13 - 0.13 |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Mon, 18 May 2026
Laser and JAK drug combo repigments vitiligo in 85% of kids - Stock Titan
Thu, 19 Feb 2026
Dermatology device maker STRATA Skin exits Nasdaq to cut costs - Stock Titan
Thu, 19 Feb 2026
STRATA Skin Sciences Confirms Nasdaq Delisting - Yahoo Finance
Wed, 18 Feb 2026
Should I buy Strata Skin Sciences (SSKN) - Zacks Investment Research
Tue, 17 Feb 2026
STRATA Skin Sciences Highlights Meta-Analysis Confirming - GlobeNewswire
Thu, 12 Feb 2026
STRATA Skin Sciences stock plunges after Nasdaq delisting notice - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 6 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 25.3 (%) |
| Shares Short | 359 (K) |
| Shares Short P.Month | 294 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | -20.4 % |
| Operating Margin | 0.4 % |
| Return on Assets (ttm) | -11.2 % |
| Return on Equity (ttm) | -159 % |
| Qtrly Rev. Growth | -3 % |
| Gross Profit (p.s.) | 3.03 |
| Sales Per Share | 5.21 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.09 |
| PEG Ratio | 0 |
| Price to Book value | 0.24 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|